Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Clinical Neuroradiology|August 23, 2018
Accuracy and Reliability of Multiphase CTA Perfusion for Identifying Ischemic CoreMeaghan Reid, Akinrinola O Famuyide, Nils D Forkert, et al.
Clinical Neuroradiology|June 5, 2019
Correction to: Accuracy and Reliability of Multiphase CTA Perfusion for Identifying Ischemic CoreMeaghan Reid, Akinrinola O Famuyide, Nils D Forkert, et al.
JMIR Serious Games|December 7, 2023
TACTICS VR Stroke Telehealth Virtual Reality Training for Health Care Professionals Involved in Stroke Management at Telestroke Spoke Hospitals: Module Design and Implementation StudySteven Maltby, Carlos Garcia-Esperon, Kate Jackson, et al.
Journal of Medicinal Chemistry|February 9, 2008
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugsJian-Xin Duan, Hailong Jiao, Jacob Kaizerman, et al.
Cancer Research|January 4, 2008
Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cellsJames W Evans, Sophia B Chernikova, Lisa A Kachnic, et al.
Science Advances|July 11, 2017
WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell deathMarcus M Fischer, Belinda Cancilla, V Pete Yeung, et al.
Molecular Cancer Therapeutics|December 8, 2011
Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302Fanying Meng, James W Evans, Deepthi Bhupathi, et al.
Frontiers in Stroke|January 16, 2026
Rollout of a statewide Australian telestroke network including virtual reality training is associated with improved hyperacute stroke workflow metrics and thrombolysis rateCarlos Garcia-Esperon, Steven Maltby, Ken Butcher, et al.
Neuroradiology|November 13, 2019
Comparison of different methods of thrombus permeability measurement and impact on recanalization in the INTERRSeCT multinational multicenter prospective cohort studyHenrik Gensicke, James W Evans, Fahad S Al Ajlan, et al.
Cell Chemical Biology|August 13, 2025
Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancersWadie D Mahauad-Fernandez, Yu Chi Yang, Ian Lai, et al.
Pageof 9